Medical Oncology | Oncology | School of Medicine

Why Queen’s Medical Oncology?

Queen’s Medical Oncology is a close-knit, two-year residency program offering individualized training in a highly supportive academic environment. Residents benefit from early clinical independence, longitudinal clinics, broad exposure across tumour sites, and close faculty mentorship within a regional cancer centre with comprehensive multidisciplinary care.

Training includes opportunities in clinical trials, research, quality improvement, community oncology, and precision oncology. Our goal is to graduate confident, well-rounded medical oncologists prepared for independent practice and academic careers.

Program Leadership

	Dr. Taylor Moffat, MD, MSc, FRCPC Program Director, Medical Oncology Residency Program Assistant Professor, Queen’s University Medical Oncologist, Kingston Health Sciences Centre
coming soon	Academic Program Coordinator

Our Current Residents and Fellow(s)

Current Residents:

Name	Medical School	Internal Medicine Residency
Dr. Maitha Al Sibani	Sultan Qaboos University, Sultanate of Oman	Oman Medical Specialty Board (OMSB), Sultanate of Oman
Dr. Elvis Obomanu	University of Portharcourt, Nigeria	Jefferson-Einstein Hospital, Philadelphia, USA
Dr. Teena Abdalla	University of Sharjah, UAE (MBBS)	McGill University, Montreal
Dr. Fahad Saeed Alqahtani	King Saud University, Saudi Arabia	Internal Medicine Residency, Saudi Arabia

Current Fellows:
2026-2027

	Name	Medical School	PhD	Residency	Focus
	Dr. Hannah Bromley	MB BCh, Cardiff University, United Kingdom	Health Economics, University of Melbourne and University of Birmingham	Clinical Oncology, The Christie Hospital, Manchester, United Kingdom	Common Sense Oncology Fellowship

Future Fellows:
2027-2028

	Name	Medical School	PhD	Residency	Focus
	Dr. Maitha Al Sibani	Sultan Qaboos University, Sultanate of Oman		Clinical Oncology, Queen's University	Clinical Research Fellowship in Lung and Gynecology

Program Overview

Queen’s Medical Oncology is a dynamic two-year residency program and was an early adopter of Competency-Based Medical Education (CBME). Our program combines comprehensive clinical training with individualized learning, progressive independence, and close faculty mentorship.

Individualized Training & Mentorship

Our program provides personalized, one-on-one learning with close faculty supervision. Residents develop increasing clinical independence throughout training while maintaining ready access to experienced faculty for support and guidance.

Longitudinal Clinic

Beginning early in training, residents have their own weekly longitudinal clinic where they follow patients over time. This provides continuity of care, progressive clinical autonomy, and the opportunity to develop meaningful physician-patient relationships.

Comprehensive Clinical & Multidisciplinary Training

Residents rotate through tumour-specific clinics and gain experience in outpatient oncology, inpatient consultation, and multidisciplinary cancer care. Residents work closely with radiation oncology, hematology, gynecologic oncology, surgical oncology, ENT, infectious diseases, palliative care, internal medicine, surgery, radiology, pathology, and other specialties.

Academic & Community Oncology

The majority of training takes place at the Cancer Centre of Southeastern Ontario (CCSEO) in Kingston, providing a comprehensive tertiary academic oncology experience. Residents also have dedicated training opportunities in community oncology at Belleville General Hospital. Exposure to both academic and community practice helps prepare graduates for careers in either setting.

Research & Scholarship

Residents have access to a broad range of research opportunities and are assigned a research mentor upon entering the program. Opportunities include clinical trials, health services and outcomes research, quality improvement, education, and translational and precision oncology research.

Sinclair Cancer Research Institute & Research Networks

Residents have access to several internationally renowned cancer research groups based at the Sinclair Cancer Research Institute (SCRI), including the Canadian Cancer Trials Group (CCTG), Cancer Care and Epidemiology (CCE), Queen’s Global Oncology (QGO), and Common Sense Oncology (CSO). Several members of these groups are also members of the Medical Oncology division, providing residents with opportunities for mentorship and collaboration.

Clinical Trials

Residents have opportunities to study clinical trials in cancer therapy, supportive care, and prevention across Canada and internationally, with exposure to the operational aspects of study conduct from an investigator perspective.

Educational & Professional Development

Residents receive support to attend major oncology conferences and educational meetings and to present and publish their research. Residents also receive access to ASCO SEP and Royal College examination preparation resources.

A Close-Knit Training Environment

Training predominantly at a single primary site fosters teamwork and strong relationships among residents, faculty, allied health professionals, and multidisciplinary colleagues. Our program provides a balance of independence and support, allowing residents to develop clinical autonomy while knowing experienced faculty are readily available for guidance.

Training Experience & Curriculum

Transition to Discipline and Foundations of Discipline (Year 1)

Most of the first year of the training program consists of the Transition to Discipline (approx. 4 weeks or 1 block) stage which emphasizes the orientation and assessment of new trainees arriving from different Internal Medicine programs and leads into the Foundations of Discipline stage (approx. 16 to 24weeks or 4 to 6 blocks). This includes rotations in:

Medical Oncology
Hematology
Palliative Care
In-patient rotations

Most of the clinical experience in medical oncology takes place in the outpatient setting. Residents are assigned to tumour specific sites and spend 2–3-month rotations attending and participating in these clinics during the first year. Residents are also involved in providing in-patient consultation services according to the site-specific rotation.

Core of Discipline (Year 1-2)

Upon successful completion of the Foundations of Discipline stage, residents begin the Core of Discipline stage (approx. 64 to 72 weeks or 16 to 18blocks) which includes rotations in:

Canadian Cancer Trials Group (CCTG): Statistical and Operations
Medical Oncology
In-patient rotations
Research
Electives

During the in-patient rotations, the resident acts as a Junior Consultant on the ward working with internal medicine house staff and with attending staff back up.

The scheduled rotations provide the trainee with the opportunity to gain experience in all aspects of the practice of medical oncology and to interact with complimentary disciples including radiation, hematology, gynecology and surgical oncology, ENT, infectious disease and palliative care. The close affiliation and good working relationship with the host hospital ensures interaction and collaboration with internal medicine, surgical and radiology specialties.

Transition to Practice (Year 2)

The final stage of training is Transition to Practice stage (4 weeks or 1 block) whereby the resident will demonstrate readiness to make the transition to autonomous practice.

Clinical Investigator Program (CIP)

For residents interested in additional training, Queen’s University also offers a Clinical Investigator Program (CIP). This program offers integrated clinical and research training and the opportunity to earn a graduate degree while completing residency. For more information, please visit https://meds.queensu.ca/academics/cip.

Canadian Cancer Trials Group (CCTG) Statistical and Operations Office Rotation

The Canadian Cancer Trials Group is a cooperative oncology group which carries out clinical trials in cancer therapy, supportive care and prevention across Canada and internationally. It is one of the national programs and networks of the Canadian Cancer Society Research Institute (CCSRI) and is supported by the Canadian Cancer Society (CCS).

CCTG has two main areas of study: investigational new drugs; and comparative randomized (phase III) trials. CCTG’s role in investigational new drug trials is to provide a centralized focus of knowledge, expertise, and experience to help Canadian investigators compete successfully for access to promising and scientifically interesting new agents. The Phase III program develops and conducts randomized trials across the spectrum of adult malignancies.

The main objective of the rotation for residents is to be exposed to the operational aspects of study conduct from an Investigator perspective including but not restricted to:

Safety oversight
Regulatory oversight, quality assurance/monitoring
Protocol development and conduct
Ethics & compliance principles including consent document generation
Data Management; data compilation, checking, and analysis

This experience will provide exposure to the knowledge and skill base required for a clinical trialist to meaningfully participate in clinical studies in oncology, and will complement other activities such as the biennial CCTG New Investigator Clinical Trials Course and the CCTG Annual Spring Meeting of Participants. Residents are encouraged to participate in clinical, translational, and health services research throughout training, with mentorship from faculty across the Department of Oncology and Queen’s University. Opportunities are available through the Sinclair Cancer Research Institute, Canadian Cancer Trials Group, Cancer Clinical Evaluation Program, and Global Oncology initiatives.

CCTG Website: https://www.ctg.queensu.ca/

Other Electives:

Flexible elective opportunities aligned with resident career goals.
Opportunities for community oncology electives
Visiting electives at other Canadian or international cancer centres, where available.
Dedicated electives in clinical trials, medical education, health services research, or global oncology.
Fellowship opportunities

Resident Opportunities and Support

Dedicated mentorship with faculty tailored to each resident’s academic and career interests.
Protected research opportunities through the Sinclair Cancer Research Institute, Canadian Cancer Trials Group (CCTG), Cancer Clinical Evaluation(CCE), Global Oncology, and other Queen’s research programs.
Opportunities to present research at provincial, national, and international meetings.
Funding support for conference attendance and research presentations, where available.
Individualized elective experiences based on resident career goals, including community oncology, clinical trials, medical education, and research.
Wellness initiatives.

Educational Activities

Professional Development

Opportunities to attend clinical trials, leadership, and educational courses.
Support for conference attendance and presentations.
Access to educational resources (e.g. UpToDate, ASCO SEP educational materials), where available.
Opportunities to participate in visiting professor rounds and educational events.
Career planning and fellowship mentorship.

Longitudinal Clinic

Once residents enter the foundations stage, residents will be given one half-day per week dedicated to their own longitudinal clinic. Residents will have oversight from a longitudinal supervisor which they will work alongside and support during the Resident Longitudinal Clinic.

Academic Half-Days

Residents are provided with a protected half day per week dedicated to learning. This includes multidisciplinary lectures, webinars, case-based learning, and individual learning.

Journal Club

This series highlights methodology and statistics, with residents alternating in leading the discussions. Dedicated AI Journal Clubs explore the evolving role of artificial intelligence in oncology, research, and clinical practice.

Resident Rounds

Each week, residents meet with faculty to discuss specific clinical cases.

Department of Oncology Grand Rounds

Residents participate in weekly Thursday morning Department of Oncology Grand Rounds, bringing together speakers and participants from across oncology specialties, including medical oncology, radiation oncology, surgical oncology, palliative care, global oncology, and medical physics.

Clinical Trials Design Series

Residents participate in monthly clinical trials design sessions led by a senior investigator and biostatistician from the Canadian Cancer Trials Group (CCTG). Sessions focus on clinical trial design, endpoints, methodology, data collection, and statistical analysis.

Training Sites

Kingston Health Sciences Centre: Kingston General Hospital

Kingston General Hospital (KGH), part of Kingston Health Sciences Centre, is a community of people dedicated to transforming the patient and family experience through innovative and collaborative approaches to care, knowledge, and leadership. As southeastern Ontario’s leading centre for complex-acute and specialty care, KGH serves almost 500,000 regional residents through its Kingston facility and 24 regional affiliate and satellite sites. Fully affiliated with Queen’s University, KGH was named as one of Canada’s top research hospitals in 2011.

Patients with oncologic conditions requiring hospital admission are admitted to the Hematology Oncology service at KGH. This is a joint service that provides care for patients with both hematological and oncologic conditions. The unit consists of thirteen beds and is supervised by an attending physician from one of the above specialties. The primary care of patients is shared by residents, a General Practitioner in Oncology, and attending staff. Residents are involved in inpatient care throughout the year as well as during their Junior Attending rotation and when on call.

Cancer Centre of Southeastern Ontario

The Cancer Centre of Southeastern Ontario (CCSEO) is a world-class facility and many of its cancer specialists are recognized internationally for their expertise in cancer treatment and research. It is also an academic cancer centre, housing the Department of Oncology and playing a vital role in educating tomorrow’s health professionals.

A major redevelopment of the CCSEO was completed in 2011. Its facilities were modernized and an additional 37,000 square feet was added to improve the patient and caregiver experience. Two new radiation treatment bunkers have been added, an HDR brachytherapy suite has been built, and the chemotherapy space has been increased from 15 treatment spaces to 39. Dedicated space for children with cancer was also created, in addition to separate areas for its palliative medicine and supportive care program.

Research & Scholarly Activity

Resident Contributions to Scholarly Activity (selected from 2020-2025)

Holstead R, Rasul R, Golden A, Kamdar D, Ghaly M, Teckie S, Frank D, Fantasia J, Seetharamu N. Identifying patterns of failure and secondary primary malignancies in HPV-related oropharyngeal squamous cell carcinomas. Future Oncol. 2020 Feb;16(6):199-207. doi: 10.2217/fon-2019-0673. Epub 2020 Jan 22. PMID: 31967480.

Holstead RG, Robinson AG. Discussing Serious News Remotely: Navigating Di cult Conversations During a Pandemic. JCO Oncol Pract. 2020 Jul;16(7):363-368. doi: 10.1200/OP.20.00269. Epub 2020 May 18. PMID: 32421390.

Kartolo A, Holstead R, Khalid S, Emack J, Hopman W, Robinson A, Baetz T. Serum neutrophil-to-lymphocyte ratio and platelet to-lymphocyte ratio in prognosticating immunotherapy e cacy. Immunotherapy. 2020 Aug;12(11):785-798. doi: 10.2217/imt 2020-0105. Epub 2020 Jul 13. PMID: 32657234.

Kartolo A, Holstead R, Khalid S, Emack J, Hopman W, Baetz T. Safety of Immunotherapy Rechallenge After Immune-related Adverse Events in Patients With Advanced Cancer. J Immunother. 2021 Jan;44(1):41-48. doi: 10.1097/CJI.0000000000000337. PMID: 32815895.

Kartolo A, Holstead R, Hopman W, Baetz T. Prognosticating role of serum eosinophils on immunotherapy e cacy in patients with advanced melanoma. Immunotherapy. 2021 Feb;13(3):217-225. doi: 10.2217/imt-2020-0265. Epub 2020 Nov 26. PMID: 33238773.

Kartolo A, Deluce J, Holstead R, Hopman W, Lenehan J, Baetz T. Impact of Baseline Corticosteroids on Immunotherapy E cacy in Patients With Advanced Melanoma. J Immunother. 2021 May 1;44(4):167-174. doi: 10.1097/CJI.0000000000000360. PMID: 33560702.

Kartolo A, Holstead RG, Duran I, Robinson AG, Vera-Badillo FE. A Systematic Review and Meta-analysis of Dual Therapy in Patients With Advanced Renal Cell Carcinoma of Favourable Risk. Urology. 2021 Nov;157:8-14. doi: 10.1016/j.urology.2021.08.023. Epub 2021 Aug 28. PMID: 34461142.

Yeung C, Kartolo A, Holstead R, Moffat GT, Hanna L, Hopman W, Lako J, Baetz T. Safety and Clinical Outcomes of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Diseases. J Immunother. 2021 Nov-Dec 01;44(9):362-370. doi: 10.1097/CJI.0000000000000377. PMID: 34121061.

Kartolo A, Yeung C, Moffat GT, Hanna L, Hopman W, Baetz T. Venous thromboembolism events in patients with advanced cancer on immune checkpoint inhibitors. Immunotherapy. 2022 Jan;14(1):23-30. doi: 10.2217/imt-2021-0151. Epub 2021 Nov 11. PMID: 34758641.

Yeung C, Kartolo A, Holstead R, Moffat GT, Hanna L, Hopman W, Baetz T. No association between BMI and immunotoxicity or clinical outcomes for immune checkpoint inhibitors. Immunotherapy. 2022 Jul;14(10):765-776. doi: 10.2217/imt-2021-0250. Epub 2022 Jun 13. PMID: 35695057.

Hanna L, Moffat GT, Hopman W, Gaudreau PO, Fung AS. A study of the efficacy and toxicity outcomes of extended durvalumab dosing in patients with stage III unresectable non-small cell lung cancer (NSCLC) during the COVID-19 pandemic. Cancer Treat Res Commun. 2023;34:100678. doi: 10.1016/j.ctarc.2022.100678. Epub 2022 Dec 30. PMID: 36608489; PMCID: PMC9801690.

Mutebi M, Dehar N, Nogueira LM, Shi K, Yabro KR, Gyawali B. Cancer Groundshot: Building a Robust Cancer Control Platform in Addition To Launching the Cancer Moonshot. ASCO Educational Book. 2022;42:1-16.

Dehar N, Meem M, Aggarwal I, Hopman W, Gaudreau P-O, Robinson A, Fung AS. Real world eligibility for clinical trials in extensive stage small cell lung cancer (ES-SCLC) patients: A single centre retrospective analysis. IASLC 2022 World Conference on Lung Cancer Abstract book. 2022; EP14.05-010;1168. Available from: https://wclc2022.iaslc.org

Moffat GT, Hanna L, Hopman W, Fung AS, Gaudreau PO. An assessment of extended pembrolizumab dosing in advanced non small-cell lung cancer in the COVID-19 pandemic. Immunotherapy. 2023 Aug;15(12):921-932. doi: 10.2217/imt-2022-0257. Epub 2023 Jul 11. PMID: 37431608; PMCID: PMC10340130.

Wright K, Mittal A, Gyawali B. Surrogate endpoints for HTA decisions of breast cancer drugs: utility and pitfalls. Curr Opin Oncol. 2023 Nov 1;35(6):513-521. doi:10.1097/CCO.0000000000000984. PMID: 37621175.

Mittal A, Kim MS, Dunn S, Wright K, Gyawali B. Frequently Asked Questions on surrogate endpoints in oncology: opportunities, pitfalls, and the way forward. eClinicalMedicine. 2024 Sep 13;doi:10.1016/j.eclinm.2024.102824.

Wilson B, Wright K, Koven R, Booth CM. Surveillance Imaging After Curative-Intent Treatment for Cancer: Bene ts, Harms, and Evidence. J Clin Oncol. 2024 May 29;JCO2302475. doi:10.1200/JCO.23.02475. PMID: 38805665.

Wright K, Booth CM. Reply to H.O. Al-Shamsi et al. J Clin Oncol. 2024 Oct 3:JCO2401689. doi:10.1200/JCO-24-01689. Epub ahead of print. PMID: 39361904.

Wilson BE, Wright K, Sengar M, Sullivan R, Pearson SA, Barton MB, Gyawali B, De Vries E, Moja L, Pramesh CS, Booth CM. Analysis of 2023 World Health Organization cancer Essential Medicines List and concordance with resource strati ed guidelines. J Natl Cancer Inst. 2025 May 23;djaf100. doi:10.1093/jnci/djaf100. Epub ahead of print. PMID: 40408185.

Wright K, Shkabari B, Booth CM, Knopf K, Tregear M, Gyawali B. Congruence of cancer screening recommendations between the USPSTF and the top ten US cancer centers: a cross sectional study. eClinicalMedicine. 2025 Apr 1;doi:10.1016/j.eclinm.2025.103169

Moffat GT, Tang W, Robinson A. Small Cell Lung Cancer in Never/Light Smokers — A Role for Molecular Testing? Journal of the National Comprehensive Cancer Network. 2023. doi:10.6004/jnccn.2022.7089.

Oral presentations (Conference)

Devereaux S, Normore J, Powell E. Adjuvant endocrine therapy in premenopausal women with high-risk hormone receptor positive breast cancer: a survey of practice variations amongst Canadian medical oncologists. Oral presentation at: Canadian Association of Medical Oncology Annual Scienti c Meeting; 2024 Oct 25.

Baron G, Frost K, Parr K, Mates M, Robinson A, Genta S, Mueller C. Monitoring of non-small cell lung cancer immunotherapy using an mDETECT liquid biopsy in comparison with CT imaging demonstrates complex tumour and ctDNA relationships [presented at Canadian Association of Medical Oncology Annual Scientific Meeting, Nov 2025]

In progress Journal Publications:

Wright K, Baron G, Wilson B. Different sites, different sights: a scoping review of how patient perceptions of the potential benefits of adjuvant systemic therapy varies between cancer patient populations [Working title]. Baron G, Verduzco H, Li Y. Geriatric assessment feasibility assessment [Working title].

Baron G, Miller A, Moffat GT. Case report: Lynch Syndrome and a pathologic complete response with immunotherapy [Manuscript in preparation].

Baron G, Robinson A, Shephard F, Wu F. Case report: ALK-mutant advanced NSCLC with pulmonary tumour thrombotic microangiopathy during pregnancy [Working title].

Devereaux S, Fairbridge N. How is the skill of prognostication taught within Canadian Medical Oncology residency programs?: A quality improvement project [Manuscript in preparation].

Devereaux S, Normore J, Powell E. Adjuvant endocrine therapy in premenopausal women with high-risk hormone receptor positive breast cancer: a survey of practice variations amongst Canadian medical oncologists [Manuscript in preparation].

Projects in progress:

Wilson B, Booth C, Moffat T, Devereaux S, Dong W. Drug discontinuation due to radiographic progression in advanced cancer: a real-world analysis.

Devereaux S, Liu S, Mates M. Patient reported outcomes in breast cancer survivors: a feasibility pilot project.

Faculty Publications (selected from 2021–2025)

Christopher M. Booth

Courneya KS, Booth CM (CHALLENGE Investigators), et al. Structured Exercise after Adjuvant Chemotherapy for Colon Cancer. N Engl J Med. 2025 Jul 3;393(1):13-25.
Wilson BE, Eisenhauer EA, Booth CM. Study Participants, Future Patients, and Outcomes That Matter in Cancer Clinical Trials. JAMA. 2024 Jun 25;331(24):2081-2083.
Del Paggio JC, Gyawali B, Wilson BE, Booth CM, et al. Cost and value of cancer medicines in a single-payer public health system in Ontario, Canada: a cross-sectional study. Lancet Oncol. 2024 Apr;25(4):431-438.
Gupta A, Kain D, Robinson AG, Booth CM, Hanna TP, et al. Trajectories of Health Care Contact Days for Patients With Stage IV Non-Small Cell Lung Cancer. JAMA Netw Open. 2024 Apr 1;7(4):e244278.

Brooke E. Wilson

Wilson BE, Wright K, Koven R, Booth CM. Surveillance Imaging After Curative-Intent Treatment for Cancer: Bene ts, Harms, and Evidence. J Clin Oncol. 2024 Jul 1;42(19):2245-2249.
Wilson BE, Hanna TP, Booth CM. Efficacy-effectiveness gaps in oncology: Looking beyond survival. Cancer. 2024 Feb 1;130(3):335-338.
Verduzco-Aguirre H, Booth CM, Wilson BE. Surveillance imaging: minimal evidence and forgotten harms. BMJ Oncol. 2025 Mar 7;4(1):e000724
Wilson BE, Wright K, Gyawali B, Booth CM, et al. Analysis of 2023 World Health Organization cancer Essential Medicines List and concordance with resource-strati ed guidelines. J Natl Cancer Inst. 2025 Oct 1;117(10):2010-2020.

Bishal Gyawali

Sharma S, Gyawali B, Hay AE, Booth CM, et al. Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials. Curr Oncol. 2021 Apr 13;28(2):1518-1527.
Gyawali B, et al. Biologics in severe asthma: a state-of-the-art review. Eur Respir Rev. 2025 Jan 8;34(175):240088
Gyawali B, Eisenhauer EA, Booth CM, Wilson BE, et al. Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials. Lancet Oncol. 2025 Feb;26(2):e80-e89.

Janet Dancey

Anagnostou V, Gaudreau PO, Dancey J, et al. ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. Nat Med. 2023 Oct;29(10):2559-2569.
Gupta AA, Dancey J, et al. Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial. EClinicalMedicine. 2024 Dec 10;79:102991.
O'Dwyer PJ, Dancey J, et al. Correlative Science in the Cooperative Group System: Re-Engineering for Success. J Clin Oncol. 2024 Nov 20;42(33):3905-3910

Wendy R. Parulekar

Goodwin PJ, Shepherd LE, Parulekar WR, et al. Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial. JAMA. 2022 May 24;327(20):1963-1973.
Sweeney Cj, Parulekar WR, et al. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2023 Apr;24(4):323-334.
Parker CC, Parulekar WR, et al. Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial. Lancet. 2024 Jun 1;403(10442):2405-2415
Conduit C, Parulekar WR, et al. Enzalutamide with standard rst-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304). Future Oncol. 2025 Mar;21(6):627-636.

Pierre-Olivier Gaudreau

Dehar N, Meem M, Gaudreau PO, Robinson A, et al. Brief Report: Real-World Eligibility for Clinical Trials in Patients With Extensive-Stage SCLC at a Tertiary Care Center. JTO Clin Res Rep. 2024 Jun 15;5(7):100696.
Spicer J, Robinson AG, Gaudreau PO, et al. A Phase II Study of Neoadjuvant Opnurasib KRAS G12C Inhibitor in Patients With Surgically Resectable Non-Small Cell Lung Cancer (CCTG IND.242A): A Substudy of the IND.242 Platform Master Protocol. Clin Lung Cancer. 2025 Mar;26(2):146-151
CCTG BR.38 Trial – “Randomized Phase III Trial of SBRT Plus Immunotherapy for Oligoprogressive Metastatic Lung Cancer” (Senior Investigator).

Francisco Vera Badillo

Zalay O, Vera-Badillo FE, et al. Adjuvant Radiotherapy for Upper Tract Urothelial Carcinoma: Systematic Review and Meta Analysis. Curr Oncol. 2022 Dec 20;30(1):19-36.
Van Wambeke S, Vera-Badillo FE, Gyawali B. Controlling the Control Arm in Metastatic Castration-Resistant Prostate Cancer Trials: Best Standard of Care or the Minimum Standard of Care? J Clin Oncol. 2022 May 10;40(14):1518-1521.
Coschi CH, Vera-Badillo F, Gaudreau PO, et al. E ects of cannabinoids on immune checkpoint inhibitor response: CCTG pooled analysis of individual patient data. Immunotherapy. 2025 Mar;17(4):257-268.
Winquist E, Vera-Badillo F, Smoragiewicz M, et al. Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2025 Jan 6;31(1):45-55.

Mihaela Mates

Semenuk LJ, Mates M, et. al. Implementing Next-Generation Sequencing Process Changes to Increase Capacity and Improve Timeliness of Molecular Biomarker Pro ling for Lung Cancer Patients. J Appl Lab Med. 2024 Mar 1;9(2):284-294.
Tera Y, Mates M. Assessing hypercoagulability and VTE risk using thromboelastography and Khorana score in women with cancers receiving chemotherapy. Am J Hematol. 2024 Apr;99 Suppl 1:S19-S27.
Dehar N, Mates M, et al. A Retrospective Analysis of Diagnostic Breast Imaging Outcomes in Young Women at a Tertiary Care Center. Curr Oncol. 2024 Jul 6;31(7):3939-3948.

Andrew G. Robinson

Robinson AG, Izard JP, Vera-Badillo FE. Treatment and Patient Selection for Patients with Metastatic Castration-resistant Prostate After Progression on Docetaxel and Abiraterone/Enzalutamide: When to Play Your CARD and When to Do Your PARP. Eur Urol. 2021 Aug;80(2):123-126.
Reck M, Robinson AG. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50. J Clin Oncol. 2021 Jul 20;39(21):2339-2349.
Novello S, Robinson AG, et al. Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. J Clin Oncol. 2023 Apr 10;41(11):1999-2006.
Garassino MC, Robinson AG, et al. Impact of Tumor Response and Response Duration on Survival Among Participants Receiving Pembrolizumab Plus Chemotherapy as First-Line Therapy for Non-Small-Cell Lung Cancer. Oncol Ther. 2025 Sep;13(3):667-681.

Gordon Taylor Moffat

Moffat GT, Hu Z-I, Meric-Bernstam F, et al. KRAS Allelic Variants in Biliary Tract Cancers. JAMA Network Open. 2024; 7(5):e249840.
Moffat GT, Wang T, Robinson AG. Small Cell Lung Cancer in Light/Never Smokers. JNCCN. 2023; 21(4):336–342.
Moffat GT, Epstein AS, O’Reilly EM. Pancreatic Cancer – A Disease in Need: Optimizing and Integrating Supportive Care. Cancer. 2019 Nov 15;125(22):3927–3935.
Lee CL, Freeman M, Moffat GT, et al. Real-World Outcomes of Atezolizumab with Bevacizumab Treatment in Hepatocellular Carcinoma Patients: Effectiveness, Esophagogastroduodenoscopy Utilization and Bleeding Complications. Cancers (Basel). 2024 Aug 19;16(16):2878.
Moffat GT, Hanna L, Gaudreau PO. An assessment of extended pembrolizumab dosing in advanced non-small-cell lung cancer in the COVID-19 pandemic. Immunotherapy. 2023 Aug;15(12):921-932.

Yuchen Li

Li Y, et al. Assessing the Feasibility and External Validity of NLP-Extracted Data for Advanced Lung Cancer Patients. Lung Cancer. 2025 Jan; 199:108080.
Li Y, et al. Use of broad-spectrum antibiotics in adult cancer patients presenting to emergency department with non neutropenic fever and/or suspected infection. Support Care Cancer. 2025 Apr 16;33(5):383
Noormohammadpour P, Li Y, et al. Differential prognostic association of systemic inflammatory biomarkers on survival outcomes in head and neck squamous cell carcinoma patients by human papillomavirus status. Neoplasia. 2025 Aug;66:101178.

Martin Smoragiewicz

Baran E, Smoragiewicz M, et al. Cancer stage documentation and accuracy: Single-center retrospective study on oropharyngeal cancers. Oral Oncol. 2025 Dec;171:107795.
Baran E, Smoragiewicz M, et al. Oropharyngeal Cancer Staging Health Record Extraction Using Artifcial Intelligence. JAMA Otolaryngol Head Neck Surg. 2024 Dec 1;150(12):1051-1057.
Wang X, Smoragiewicz M, et al. Mainstream Model of Genetic Testing for Prostate Cancer at a Large Tertiary Cancer Centre. Clin Genitourin Cancer. 2024 Jun;22(3):102052.

Rania Chehade

Fan KY, Chehade R, et al. Surgery versus definitive radiotherapy in the management of stage I-II small cell neuroendocrine carcinoma of the cervix: A systematic review and meta-analysis. Gynecol Oncol. 2025 Nov 26;204:118-123.
Fan KY, Chehade R, et al. Association Between Human Epidermal Growth Factor Receptor 2-Low Status and Time to Development of Brain Metastases Among Patients With Breast Cancer: A Retrospective Cohort Study. JCO Precis Oncol. 2025 Mar;9:e2400641.
Chehade R, et al. Advances in Vulvar Cancer Biology and Management. J Clin Oncol. 2025 Jan;43(1):89-100

Previous Fellows and Fellowships

Fellowship Director: Dr. Francisco Vera-Badillo

Sites of interest:

Previous Fellows:

Year	Trainee	Fellowship Type	Current Position
2019-2020	Dr. Michael Raphael	Advanced Cancer Health Services Research Fellowship	University of Toronto/ Odette Cancer Centre, Sunnybrook Health Sciences Centre
2020-2021	Dr. Adam Fundytus	Clinical Research Fellowship in GI and GU Oncology	BC Cancer, Victoria
2021-2022	Dr. Adi Kartolo	Clinical Research Fellowship in Melanoma / Canadian Clinical Trials Group (CCTG)	McMaster University/ Juravinski Cancer Centre
2023-2024	Dr. Navdeep Dehar	Fellowship in Precision Oncology with CCTG	University of Calgary/ Arthur Child Comprehensive Cancer Centre
2024-2025	Dr. Haydee Verduzco-Aguirre	Common Sense Oncology Fellowship	National Institute of Health Sciences and Nutrition, Mexico City, Mexico
2024-2025	Dr. Adam Miller	Clinical Fellowship in GI and GU Oncology	Bluewater Health, Sarnia
2025-2026	Dr. Sam Stevens	Common Sense Oncology Fellowship	Illawarra Shoalhaven Local Health District, New South Wales, Australia
2025-2026	Dr. Kristin Wright	Cancer Care & Epidemiology (CCE) and CAMO Fellowship	Queen’s University/KHSC

Equity, Diversity, Inclusion & Indigeneity (EDII)

The Queen's Medical Oncology training program welcomes diversity among its trainees and seeks to foster an environment that is welcoming to all, regardless of gender identity, race, religion, or sexual orientation.

We are committed to advancing equitable and inclusive practices. Please refer to the PGME website for additional information / resources including QHS EDIIA Initiatives and EDIIA statements (Indigenous Land Acknowledgement, Anti-Discrimination Statement, Inclusion Statement, and Statement on Social Accountability)

Internal Medicine Residents

Welcome to the Division of Medical Oncology. We hope you enjoy your rotation with us and find it a valuable opportunity to gain experience in the care of patients with cancer. Please feel free to discuss any questions or concerns with our staff, Lead/Chief Resident, or Academic Program Coordinator.

Before your rotation, you will receive your schedule by email. This will include known post-call days, Internal Medicine resident clinics, and confirmed absences through your home program. Please review your schedule and let the Academic Program Coordinator know of any discrepancies or additional absences.

At orientation, you will also receive our Medical Oncology Rotation Guide, which provides an overview of the rotation, expectations, key clinical information, and resources for Internal Medicine residents.

Please note that clinical email correspondence will be sent to your KHSC email account rather than your Queen’s account, as patient information may need to be communicated securely. Please check your KHSC email regularly during the rotation.

About the Rotation

Your rotation will include a mixture of new patient consultations, treatment and follow-up clinics, and inpatient oncology consultations. You will participate in patient assessments and work with your supervising medical oncologist to develop appropriate investigation, management, and treatment plans.

Acute Oncology Experience

Residents may also participate in the assessment and management of urgent oncology issues through the Chemotherapy Emergency Pager and our Semi-Urgent Systemic Assessment Clinic/Cancer Care Assessment Unit (SUSAC/CCAU). This may include infusion and hypersensitivity reactions, treatment-related toxicities, and other acute medical concerns, with direct staff supervision.

If you are paged to the Chemotherapy Unit, please proceed promptly and let the physician you are working with know that you have been called away. You will not be managing these situations alone. The attending medical oncologist will also be contacted and available to support you.

Feedback and Evaluations

Feedback is an important part of the rotation, and we encourage you to seek feedback regularly from the physicians you work with.

Your final evaluation will incorporate feedback from your preceptors and will be reviewed with you by one of the medical oncologists with whom you have worked closely.

If you require a mini-CEX, please let your evaluator know at the beginning of clinic so that an appropriate clinical encounter can be observed. We encourage you to identify your evaluation requirements and connect with the appropriate physicians early in the rotation.

We also value your feedback. At the end of the rotation, you will receive an evaluation of the rotation from your home program. Please complete this within one week, as your feedback helps us continue to improve the experience for future residents.

Questions or Concerns

If you have any questions before or during your rotation, please contact the Academic Program Coordinator.

We look forward to working with you and hope you have an excellent rotation with Medical Oncology.

Electives & Observerships

Queen's University offers Visiting Electives for postgraduate medical trainees (residents and fellows) from other Ontario universities, Canadian universities outside Ontario, and international locations who need short-term training to complete their home program requirements.

Key Requirements and Guidelines

Duration: Electives have a maximum duration of 4 weeks, and standard rotations are typically set for 2 weeks.
Application Deadlines: Trainees from outside Ontario must submit requests at least 90 business days in advance to allow time for processing the Letter of Appointment and the College of Physicians and Surgeons of Ontario (CPSO) registration.
Application Process: All requests must go through the Postgraduate Medical Education | School of Medicine office. Trainees cannot make direct arrangements with individual departments or clinical supervisors outside of the PGME office framework.
Licensure & Fees: Visiting residents must secure appropriate provincial medical registration (such as a CPSO certificate of registration for Ontario) and meet all immigration or funding requirements if coming from outside Canada.

Observerships:

An observership is a short‑term, non‑clinical learning experience that allows individuals to observe clinical care, educational activities, or department operations within the hospital environment.

Observers do not provide patient care or make clinical decisions and therefore do not require a medical license from the College of Physicians and Surgeons of Ontario (CPSO). As a result, observerships do not fall under the oversight or registration processes of the Postgraduate Medical Education Office.

If you are interested in observing a Medical Oncology clinic, please reach out to OncEdCoord@KingstonHSC.ca.

Life in Kingston

Kingston offers the advantages of a vibrant university city with the accessibility and sense of community of a smaller centre. Located on the waterfront of Lake Ontario, the city offers a lively downtown, restaurants and cafés, arts and cultural activities, and easy access to outdoor recreation.

Kingston is centrally located between Toronto, Ottawa, and Montréal, making it easy to stay connected to larger urban centres while enjoying a manageable commute and excellent quality of life.

Learn more about living and training in Kingston through Queen’s Postgraduate Medical Education.
https://meds.queensu.ca/academics/postgraduate/prospective/kingston

How to Apply / Contact Us

The Medical Oncology Training Program particpates in the Canadian Resident Matching Service (CaRMS). Please review the Fall Sub-specialty Residency Match program description, timelines and application details.

Please feel free to contact the Program Director and/or the Academic Program Coordinator with any questions you may have.

Dr. Taylor Moffat, MD, MSc, FRCPC
Program Director, Medical Oncology Residency Program
Assistant Professor, Queen’s University
Medical Oncologist, Kingston Health Sciences Centre

Email: Taylor.Moffat@kingstonhsc.ca

Academic Program Coordinator

Email: oncedcoord@kingstonhsc.ca